Doximity Beheer
Beheer criteriumcontroles 3/4
De CEO Doximity is Jeff Tangney, benoemd in Apr2010, heeft een ambtstermijn van 14.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 298.87K, bestaande uit 98.7% salaris en 1.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 27.21% van de aandelen van het bedrijf, ter waarde $ 2.45B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 9.2 jaar.
Belangrijke informatie
Jeff Tangney
Algemeen directeur
US$298.9k
Totale compensatie
| Percentage CEO-salaris | 98.7% |
| Dienstverband CEO | 14.6yrs |
| Eigendom CEO | 27.2% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 9.2yrs |
Recente managementupdates
Recent updates
Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%
Nov 13
Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?
Nov 02Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?
Oct 15Doximity: Downgrade To Hold On Valuation Concerns
Oct 03Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors
Sep 23There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump
Aug 18Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns
Aug 10Doximity Faces Slower Revenue Growth As R&D Costs May Rise
Jul 23Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?
Jul 23At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?
Jul 01Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking
Jun 09Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)
May 17Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal
May 04Doximity: Significant Upside Remains, But Not Until The Growth Story Returns
Apr 29With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For
Apr 16Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)
Mar 26Doximity: Rating Upgrade To Buy As Outlook Turns Positive
Feb 21We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit
Feb 15What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?
Feb 13Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan
Jan 16Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital
Jan 04Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price
Dec 14Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism
Nov 10Doximity: Adding Value Using AI But Faces Near-Term Risks
Nov 01Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?
Oct 30Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively
Sep 25Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook
Aug 24Doximity Earnings: Too Many Problems, Sell
Aug 09A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)
Jul 29Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching
Jul 09Doximity: Continue To See Positive Upside From Current Stock Level
Jul 05The Returns At Doximity (NYSE:DOCS) Aren't Growing
Jun 21Doximity: Digital Health Play With Strong Fundamentals
Jun 21A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)
Apr 07Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return
Mar 20Doximity: Good Business But Extremely Overvalued
Feb 18Doximity Q3 Earnings: Disappointing Results
Feb 10Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$174m |
| Jun 30 2024 | n/a | n/a | US$161m |
| Mar 31 2024 | US$299k | US$295k | US$148m |
| Dec 31 2023 | n/a | n/a | US$138m |
| Sep 30 2023 | n/a | n/a | US$123m |
| Jun 30 2023 | n/a | n/a | US$119m |
| Mar 31 2023 | US$244k | US$240k | US$113m |
| Dec 31 2022 | n/a | n/a | US$119m |
| Sep 30 2022 | n/a | n/a | US$141m |
| Jun 30 2022 | n/a | n/a | US$148m |
| Mar 31 2022 | US$243k | US$240k | US$133m |
| Dec 31 2021 | n/a | n/a | US$107m |
| Sep 30 2021 | n/a | n/a | US$57m |
| Jun 30 2021 | n/a | n/a | US$30m |
| Mar 31 2021 | US$21m | US$240k | US$22m |
Compensatie versus markt: De totale vergoeding ($USD 298.87K ) Jeff } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.74M ).
Compensatie versus inkomsten: De vergoeding van Jeff is het afgelopen jaar met meer dan 20% gestegen.
CEO
Jeff Tangney (51 yo)
14.6yrs
Tenure
US$298,869
Compensatie
Mr. Jeffrey A. Tangney, also known as Jeff, Co-Founded Doximity, Inc. in 2010 and has been its Chief Executive Officer and Director since April 2010 and serves as its Chairperson. Mr. Tangney also serves a...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 14.6yrs | US$298.87k | 27.21% $ 2.4b | |
| Co-Founder & Chief Strategy Officer | no data | US$305.47k | 0.26% $ 23.3m | |
| Chief Financial Officer | 3.8yrs | US$3.87m | 0.13% $ 11.3m | |
| General Counsel & Corporate Secretary | 4.3yrs | US$603.94k | 0.0032% $ 284.4k | |
| Senior Vice President of Commercial Operations | 1.5yrs | US$5.21m | 0.011% $ 1.0m | |
| Co-founder and SVP People & Ops | no data | geen gegevens | geen gegevens | |
| Chief Technology Officer | no data | geen gegevens | geen gegevens | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Head of Corporate Communications | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Engineering | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Product | no data | geen gegevens | geen gegevens | |
| Senior VP & GM Commercial Products | 1.5yrs | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
45.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DOCS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 14.6yrs | US$298.87k | 27.21% $ 2.4b | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 4.2yrs | US$239.94k | 0.0025% $ 227.7k | |
| Independent Director | 13.7yrs | US$241.94k | 0.16% $ 14.8m | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 4.7yrs | US$233.94k | 0.0055% $ 494.0k |
9.2yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DOCS wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.2 jaar).